Strong Revenue and EBITDA Margin
Bavarian Nordic reported a revenue of DKK5.7 billion for 2024 with a 28% EBITDA margin, marking the fifth consecutive year of profitable growth.
Travel Health Vaccine Franchise Growth
The Travel Health vaccine franchise grew by 22% compared to the previous year, driven by a 16% increase in rabies vaccine sales and a 19% increase in TBE vaccine sales.
Public Preparedness Success
Secured contracts for more than 3 million doses due to the mpox public health crisis, with revenues much higher than the base business.
Successful Tech Transfer
Tech transfer for rabies and TBE assets is on track, with rabies completed and TBE expected to be completed this year.
New Pipeline Assets
Announced two new pipeline assets for Lyme disease and Epstein-Barr virus, with clinical studies planned for 2026.
Chikungunya Vaccine Approvals
Chikungunya vaccine approved in the U.S. and EU, with plans to launch in major territories in the first half of the year.